“…The choice of LIDO over other possible drugs targeting cell bodies (e.g., muscimol or 6-cyano-7-nitroquinoxaline-2,3-dione) but not the fibers en passage was based on our quite extensive experience with this drug infused in various brain areas such as the dorsal and ventral hippocampus and mPFC (Pereira de Vasconcelos et al, 2006;Klur et al, 2009;Lopez et al, 2012;Loureiro et al, 2012). In these experiments, using the 2-deoxyglucose method to map cerebral glucose metabolism (and behavioral evaluations in parallel), we showed that the LIDO diffusion area was mostly confined around the infusion site without any major changes in surrounding or in some distant brain structures (Pereira de Vasconcelos et al, 2006;Lopez et al, 2012). In addition, the use of a drug that does not target a specific neurotransmission system appeared more appropriate to us, because an imbalance between inhibition/excitation in some thalamic nuclei might have side effects other than only inhibition including triggering seizures (Steriade, 2006).…”